SCHEMBL3370356

SCHEMBL3370356

CCCCOc1ccc(CS(=O)(=O)N2CCCC2c2nnc(-c3ccncc3)o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 6/20 0.51
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
HSD17B10 Q99714 5/20 0.51
TSHR P16473 4/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
CYP2D6 P10635 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.37
FKBP1A P62942 3/20 0.37
HCRTR1 O43613 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3366078 0.89 HCRTR1 (0.46) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL3367339 0.88 CYP2C19 (0.43) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL3370504 0.84 CYP2C19 (0.43) ALDH1A1KDM4ELMNAMAPTHPGD
SCHEMBL3368142 0.84 CYP2C19 (0.44) ALDH1A1KDM4ENPC1RAB9AHPGD
SCHEMBL3366253 0.84 CYP2C19 (0.44) ALDH1A1KDM4ENPC1RAB9AHSD17B10
SCHEMBL3370281 0.81 MAPT (0.44) ALDH1A1KDM4ENPC1RAB9AMAPT
SCHEMBL3366848 0.78 ALDH1A1 (0.48) ALDH1A1KDM4ERAB9ALMNAMAPT
SCHEMBL3367004 0.77 CYP2C19 (0.41) ALDH1A1KDM4ERAB9ALMNAMAPT
SCHEMBL3370780 0.77 CYP2C19 (0.41) ALDH1A1KDM4ERAB9AMAPTSMN1; SMN2
SCHEMBL3368542 0.76 GPR142 (0.48) ALDH1A1KDM4ECYP3A4CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1532141-B1 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS GRUENENTHAL GMBH (DE) 2010-10-13 EP disclosed
US-7105538-B2 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2006-09-12 US disclosed
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187260-A1 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants OPRD1, OPRK1, GRIN2C ALDH1A1 510/4885KDM4E 1219/4885NPC1 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.